Daniel P. Petrylak, MD, professor of Medicine and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the KEYNOTE-045 trial, a phase III open-label study of pembrolizumab (Keytruda) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial carcinoma.
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More